Drug Approval | March 31, 2026
Teva hits major biosimilar milestones with FDA nod and regulatory filings
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Capital infusion to accelerate Earendil’s R&D platform
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
Call it a major breakthrough for diagnostic imaging
Subscribe To Our Newsletter & Stay Updated
